[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"scrotum-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:scrotum-disease":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,46,70,98],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100634868","phase-4-is-icg-imaging-safe-and-accurate-to-predict-testicular-torsion-100634868",false,"NCT07545278","Is ICG Imaging Safe and Accurate to Predict Testicular Torsion?","Assessment of Diagnostic Accuracy of Indocyanine Green Fluorescence Imaging in Children and Young People With Testicular Pain Requiring Surgical Exploration Is ICG Imaging Safe and Accurate to Predict Testicular Torsion?","Inclusion Criteria:\n\n* All children presenting with testicular pain, being taken to theatre for scrotal exploration at Sheffield Children's NHS Foundation Trust. Aged 0-19 years of age.\n\nExclusion Criteria:\n\n* Children with any allergy to contrast medium or iodine will be excluded.\n* Any family or young person \\> age 13 years refusing consent.\n* Children without a GP will not be exempt from recruitment. No information is required from community care.",true,"MALE","19 Years",{"count":20,"type":21},107,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","Testicular torsion is a time critical condition for children and young people (CYP). It is difficult to diagnose without an operation. Missing it means the child will lose a testicle. There are no good diagnostic tests, only tests that delay the child's journey to theatre, which puts them at further risk of losing the testicle. Most boys with a painful testicle get a surgical exploration to see if it is torsion and to twist and fix it. Up to 85% of children having surgery will not have torsion. They will have something they didn't need surgery for. We want to see whether a new, low risk, fast investigation could be used to diagnose the problem, meaning no torsions are missed and less children have unnecessary surgery.",[27,28],"Torsion Testis","Scrotum Disease",[30,31,32],"torsion of testis","indocyanine green","acute scrotrum","RECRUITING","2026-04-15",{"date":36,"type":37},"2026-04-22","ACTUAL",{"date":39,"type":37},"2025-04-30",{"date":41,"type":21},"2026-06-30",{"name":43,"class":44},"Sheffield Children's NHS Foundation Trust","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":45},"100602003","phase-2-a-study-of-disitamab-vedotin--bicalutamide-in-her2ar-positive-scrotal-pagets-disease-100602003","NCT07117851","A Study of Disitamab Vedotin + Bicalutamide in HER2\u002FAR-Positive Scrotal Paget's Disease","A Prospective, Single-Arm Clinical Study of Disitamab Vedotin Combined With Bicalutamide in HER2 and AR-Expressing Scrotal Paget's Disease","Inclusion Criteria:\n\n* Voluntarily sign the informed consent form and comply with the requirements of the protocol.\n* Age ≥ 18 years old.\n* Confirmed diagnosis by histological examination and\u002For cytological examination, combined with imaging or ultrasound assessment for mammary and extramammary Paget's disease; pathologically confirmed as HER2 positive, i.e., immunohistochemical test HER2 ≥ 1+, and AR positive, i.e., immunohistochemical test AR ≥ 1+.\n* ECOG score: 0 to 1.\n* At least one measurable lesion (according to the RECIST criteria, non-nodal lesions with a longest diameter on CT scan ≥10 mm, and nodal lesions with a shortest diameter on CT scan ≥15 mm); or skin lesions that can be evaluated according to the WHO criteria.\n* Adequate organ function: Blood routine: Absolute Neutrophil Count (ANC) ≥1.5×10\\^9\u002FL, Platelet (PLT) ≥70×10\\^9\u002FL, Hemoglobin (HGB) ≥80g\u002FL; Liver function: Total Bilirubin (TBIL) ≤1.5×Upper Limit of Normal Value (ULN); Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) ≤3×ULN; Serum Albumin ≥28 g\u002FL; Alkaline Phosphatase (ALP) ≤5×ULN; If the subject has received routine liver protection treatment and meets the above standards, and is stable for at least one week after assessment by the researcher, they may be enrolled; Renal function: Serum Creatinine (Cr) ≤1.5×ULN, or Creatinine Clearance ≥50 mL\u002Fmin (using the standard Cockcroft-Gault formula): Coagulation function: International Normalized Ratio (INR) ≤1.5 \u002F Prothrombin Time (PT) ≤1.5×ULN, Activated Partial Thromboplastin Time (aPTT) ≤1.5×ULN; - If the subject is receiving anticoagulant therapy, as long as PT and INR are within the range specified for the anticoagulant medication, it is acceptable.\n* Estimated life expectancy ≥3 months.\n\nExclusion Criteria:\n\n* Have a history of immunodeficiency, including HIV positive or other acquired or congenital immunodeficiency diseases, or a history of organ transplantation;\n* Have had active autoimmune diseases within 2 years prior to the start of the study treatment that required systemic treatment (such as the use of disease-modifying drugs, corticosteroids, or immunosuppressants), except for replacement therapies (e.g., thyroid hormone, insulin, or physiological corticosteroids for adrenal or pituitary insufficiency); currently receiving systemic glucocorticoid therapy or any other form of immunosuppressive therapy.\n* The dose is \\>10mg\u002Fday of prednisone or other equivalent hormones, and it is within 2 weeks of the first administration and still in use;\n* Have a history of active tuberculosis;\n* Have uncontrollable, recurrent drainage of ascites, pericardial effusion, or pleural effusion;\n* Have undergone major organ transplantation;\n* Received major surgical treatment, incisional biopsy, or significant traumatic injury within 28 days prior to the start of the study treatment; or have chronic non-healing wounds or fractures;\n* Have a history of live attenuated vaccine administration within 14 days prior to the start of the study treatment or plan to receive live attenuated vaccine vaccination during the study period;\n* Have had a severe hypersensitivity reaction after the use of monoclonal antibodies; known allergy to the active ingredients or excipients of this study drug;\n* Within 4 weeks prior to the start of the study, are participating in or have participated in other clinical studies;\n* Have a history of severe allergies;\n* Have a risk of bleeding, or coagulation dysfunction, or are currently receiving -thrombolytic therapy;\n* Have a history of substance abuse and are unable to quit or have mental disorders;\n* According to the investigator's judgment, there are concomitant diseases that seriously endanger the safety of the subject or affect the completion of the study, or there are other reasons deemed unsuitable for enrollment by the investigator.","18 Years",{"count":55,"type":21},20,[57],"PHASE2","The goal of this clinical trial is to learn if Disitamab Vedotin combined with Bicalutamide works to treat advanced HER2-positive and AR- positive extramammary Paget disease of the scrotum. It will also learn about the safety of this combination. All patients received Disitamab Vedotin every 2 weeks and Bicalutamide everyday. Follow-up was conducted until disease progression, intolerable adverse reactions occur withdrawal of informed consent by the subject, loss to follow-up, or death. Clinical tumor imaging assessments were performed using RECIST during the treatment process.",[60,28],"Extramammary Paget Disease","2025-08-05",{"date":63,"type":37},"2025-08-12",{"date":65,"type":37},"2025-08-01",{"date":67,"type":21},"2027-12-30",{"name":69,"class":44},"Fudan University",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":22,"phases":80,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":45},"100576882","phase-2-a-study-of-rc48-adc-combined-with-js001-for-advanced-extramammary-paget-disease-of-the-scrotum-100576882","NCT06791070","A Study of RC48-ADC Combined With JS001 for Advanced Extramammary Paget Disease of the Scrotum","A Prospective Multicenter Clinical Trial on the Efficacy and Safety of RC48-ADC (Disitamab Vedotin) Combined With Toripalimab in Advanced HER2-positive Extramammary Paget Disease of the Scrotum","RC48&J for EPD","Inclusion Criteria:\n\nVoluntarily sign the informed consent form and comply with the requirements of the protocol.\n\nAge ≥ 18 years old. Confirmed diagnosis by histological examination, combined with imaging assessment for scrotal extramammary Paget's disease; pathologically confirmed as HER2 positive, i.e., immunohistochemical test HER2 ≥ 1+.\n\nECOG score: 0 to 1. At least one measurable lesion (according to the RECIST criteria, non-nodal lesions with a longest diameter on CT scan ≥10 mm, and nodal lesions with a shortest diameter on CT scan ≥15 mm); or skin lesions that can be evaluated according to the WHO criteria.\n\nAdequate organ function: Blood routine: Absolute Neutrophil Count (ANC) ≥1.5×10\\^9\u002FL, Platelet (PLT) ≥70×10\\^9\u002FL, Hemoglobin (HGB) ≥80g\u002FL; Liver function: Total Bilirubin (TBIL) ≤1.5×Upper Limit of Normal Value (ULN); Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) ≤3×ULN; Serum Albumin ≥28 g\u002FL; Alkaline Phosphatase (ALP) ≤5×ULN; If the subject has received routine liver protection treatment and meets the above standards, and is stable for at least one week after assessment by the researcher, they may be enrolled; Renal function: Serum Creatinine (Cr) ≤1.5×ULN, or Creatinine Clearance ≥50 mL\u002Fmin (using the standard Cockcroft-Gault formula): Coagulation function: International Normalized Ratio (INR) ≤1.5 \u002F Prothrombin Time (PT) ≤1.5×ULN, Activated Partial Thromboplastin Time (aPTT) ≤1.5×ULN; If the subject is receiving anticoagulant therapy, as long as PT and INR are within the range specified for the anticoagulant medication, it is acceptable.\n\nEstimated life expectancy ≥3 months.\n\nExclusion Criteria:\n\nHave a history of immunodeficiency, including HIV positive or other acquired or congenital immunodeficiency diseases, or a history of organ transplantation; Have had active autoimmune diseases within 2 years prior to the start of the study treatment that required systemic treatment (such as the use of disease-modifying drugs, corticosteroids, or immunosuppressants), except for replacement therapies (e.g., thyroid hormone, insulin, or physiological corticosteroids for adrenal or pituitary insufficiency); currently receiving systemic glucocorticoid therapy or any other form of immunosuppressive therapy. The dose is \\>10mg\u002Fday of prednisone or other equivalent hormones, and it is within 2 weeks of the first administration and still in use; Have a history of active tuberculosis; Have uncontrollable, recurrent drainage of ascites, pericardial effusion, or pleural effusion; Have undergone major organ transplantation; Received major surgical treatment, incisional biopsy, or significant traumatic injury within 28 days prior to the start of the study treatment; or have chronic non-healing wounds or fractures; Have a history of live attenuated vaccine administration within 14 days prior to the start of the study treatment or plan to receive live attenuated vaccine vaccination during the study period; Have had a severe hypersensitivity reaction after the use of monoclonal antibodies; known allergy to the active ingredients or excipients of this study drug; Within 4 weeks prior to the start of the study, are participating in or have participated in other clinical studies; Have a history of severe allergies; Have a risk of bleeding, or coagulation dysfunction, or are currently receiving -thrombolytic therapy; Have a history of substance abuse and are unable to quit or have mental disorders; According to the investigator's judgment, there are concomitant diseases that seriously endanger the safety of the subject or affect the completion of the study, or there are other reasons deemed unsuitable for enrollment by the investigator.","80 Years",{"count":55,"type":21},[57],"The goal of this clinical trial is to learn if Disitamab Vedotin combined with Toripalimab works to treat advanced HER2-positive extramammary Paget disease of the scrotum. It will also learn about the safety of this combination. The main questions it aims to answer are: Does this combination reduce tumor volume and delay disease progression? What medical problems do participants have when receving this combination? Participants will: Intravenous using this combination every 3 weeks until disease progression or intolerable adverse reactions occur. Visit the clinic once every 3 weeks for checkups and tests.",[83,28],"Paget Disease, Extramammary",[85,86,87,88],"extramammary Paget disease","Disitamab Vedotin","Toripalimab","RC48-ADC","2025-01-19",{"date":91,"type":37},"2025-01-24",{"date":93,"type":21},"2025-01",{"date":95,"type":21},"2028-01",{"name":97,"class":44},"Fujian Medical University Union Hospital",{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":105,"enrollmentInfo":106,"targetDuration":4,"studyType":22,"phases":108,"briefSummary":109,"conditions":110,"keywords":112,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":125,"locationsCount":45},"100447872","phase-4-evaluation-of-botox-treatment-on-chronical-scrotal-pain-100447872","NCT05112081","Evaluation of Botox Treatment on Chronical Scrotal Pain","Evaluation of Botox Treatment in Patients With Chronic Scrotal Pain: a Randomized Double Blinded Control Trial","Inclusion Criteria:\n\n1. Age of 18 - 70 years\n2. Unilateral or bilateral scrotal pain \\> 3 months\n3. No other identifiable cause of pain\n4. Insufficient effect of conservative treatment\n5. A positive effect of local anesthesia spermatic cord block\n\nExclusion Criteria:\n\n1. Inability to provide informed consent\n2. Interest in trying to conceive with partner in the following 6 months\n3. Local infection near the proposed injection site\n4. History with an allergic reaction to BTX and \u002F or human serum albumin\n5. History of motor neuron disease or hemostatic disorder\n6. Active urogenital cancer\n7. Current use of botox injections which would result in a total dose of botox higher than 300 IE in the span of 3 months","70 Years",{"count":107,"type":21},50,[24],"The aim of the study is to evaluate the effect of botox injections at the spermatic cord in patients with chronical scrotal pain.\n\nA lot of patients experiences depressive symptoms and a lot feel isolated. The etiology if not fully understood and the condition poses a challenge for physicians.\n\nThe is no efficient minimal invasive treatment for these patients, and in severe cases patients are having there testicle removed.\n\nBy inject botox around the spermatic cord the investigators hope to relieve some of the pain in these patients and offer patients a new minimal invasive treatment.\n\nThe investigators aim to include 50 patients in this study, There will be randomised 1:1 to either the intervention arm (Botox) or control arm (sterile saline). Both patients and physicians will be blinded to the treatment.\n\nPatients will undergo a thorough physical examination and will be asked to fill out questionaries to asses their quality of life.\n\nAfter inclusion, patients will be followed closely for three months with physical examination and questionnaires.\n\nAfter three months, patients in the control arm will have the opportunity to cross over to the intervention arm.\n\nData will be reported continuously.",[28,111],"Chronic Pain",[113,114,115,116,117],"Chronical scrotal pain","CSP","Botox","BTX","minimal invasive procedure","NOT_YET_RECRUITING","2022-04-19",{"date":121,"type":37},"2022-04-20",{"date":123,"type":21},"2022-06-01",{"date":41,"type":21},{"name":126,"class":44},"Nicolai Skov Schiellerup"]